Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Deoxybouvardin targets EGFR, MET, and AKT signaling to suppress non-small cell lung cancer cells ; volume:14 ; number:1 ; day:6 ; month:9 ; year:2024 ; pages:1-15 ; date:12.2024
Scientific reports ; 14, Heft 1 (6.9.2024), 1-15, 12.2024
- Urheber
-
Nam, A-Young
Joo, Sang Hoon
Khong, Quan T.
Park, Jisu
Lee, Na Yeong
Lee, Seung-On
Yoon, Goo
Park, Jin Woo
Na, MinKyun
Shim, Jung-Hyun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-70823-7
- URN
-
urn:nbn:de:101:1-2411222110534.436571141829
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nam, A-Young
- Joo, Sang Hoon
- Khong, Quan T.
- Park, Jisu
- Lee, Na Yeong
- Lee, Seung-On
- Yoon, Goo
- Park, Jin Woo
- Na, MinKyun
- Shim, Jung-Hyun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities
Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition
Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells
Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells
Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities
Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition
Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells
Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Lentiviral vector-mediated RBM5 overexpression downregulates EGFR expression in human non-small cell lung cancer cells
Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities
Deoxybouvardin-glucoside induces apoptosis in non-small cell lung cancer cells by targeting EGFR/MET and AKT signaling pathway
Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Multicenter real-world analysis of combined MET and EGFR inhibition in patients with non-small cell lung cancer and acquired MET amplification or polysomy after EGFR inhibition
Isothiocyanates induce oxidative stress and suppress the metastasis potential of human non-small cell lung cancer cells
Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer